Brain-Eating Amoeba Statistics in the US 2026 | Cases, Deaths, Survival Rate, Facts

What is Brain-Eating Amoeba Infection?

The brain-eating amoeba, scientifically known as Naegleria fowleri, is a free-living, single-celled organism that thrives in warm freshwater lakes, rivers, hot springs, and poorly maintained pools across the United States. When water containing the amoeba enters the body through the nose — typically during swimming, diving, or water sports — it can travel along the olfactory nerve directly into the brain, causing a rare but almost universally fatal infection called primary amebic meningoencephalitis (PAM). Despite its terrifying nickname and heavy media coverage every summer, the CDC confirms that Naegleria fowleri infections remain extraordinarily rare in the United States, with typically fewer than 10 confirmed cases occurring nationwide in any given year.

What makes 2026 a notable year to examine brain-eating amoeba statistics is the continued northward geographic spread of confirmed cases into states like Missouri, South Carolina, and now Louisiana, alongside genuine — if still very early — progress on treatment options that may finally begin to move the needle on a fatality rate that has hovered above 97% for decades. The CDC’s most recently updated national dataset, refreshed in March 2026, provides the clearest and most current picture yet of exactly how many Americans have been infected, where, when, and who is most at risk. This report compiles the most current, verified brain-eating amoeba statistics for the US in 2026, covering total case counts, mortality and survival data, state-by-state exposure patterns, age and sex breakdowns, seasonal risk periods, and the latest treatment developments.

Interesting Facts About Brain-Eating Amoeba in the US 2026

Source: Centers for Disease Control and Prevention (CDC), Naegleria fowleri Data page (updated March 2026, published May 2026)

As a content writer breaking down these figures, the most important thing to understand is the scale of the discrepancy between how much public attention brain-eating amoeba infections receive each summer and how genuinely rare they are: 180 total confirmed cases across nearly 90 years of US recordkeeping works out to an average of roughly two cases per year, even though the CDC notes the yearly count has ranged as high as eight in a single year. That said, the CDC’s own 2017 research letter estimating the true annual case burden at closer to 16 cases — implying that 70% to 80% of actual infections may go undiagnosed or unreported — suggests the officially confirmed numbers likely understate the disease’s real-world frequency, even if the true figure remains small in absolute terms.

The survival statistics are what make this infection so uniquely alarming from a public health standpoint: with only 4 confirmed survivors out of 167 cases tracked between 1962 and the early 2020s, the fatality rate sits above 97%, making PAM one of the deadliest infectious diseases tracked by the CDC in terms of raw case-fatality ratio — considerably higher than diseases like rabies-adjacent conditions that receive comparable public fear, and far higher than nearly any other water-associated illness Americans might encounter during a typical summer at the lake.

US Brain-Eating Amoeba Case Statistics 2026

Source: CDC Naegleria fowleri Data page

The CDC’s official national tally, refreshed as of March 2026, confirms a total of 180 primary amebic meningoencephalitis cases diagnosed in the United States going all the way back to 1937, with cases from the earliest years of that period — 1937 through 1961 — having been identified retrospectively as diagnostic and surveillance capabilities improved over subsequent decades. Even accounting for nearly nine decades of tracking, the annual case count has never exceeded eight in any single year, reinforcing just how consistently rare this infection has remained even as US population, freshwater recreation, and diagnostic awareness have all increased substantially over the same period.

Different reporting windows commonly appear across various sources covering this topic, which can create some confusion: the frequently cited “157 cases from 1962 to 2022” figure reflects an older CDC dataset snapshot, while the more recently updated figure of 167 cases extends that same 1962 starting point through 2025, capturing an additional decade of cases beyond the older, widely circulated statistic. Readers encountering both figures in different sources should understand they are not contradictory — they simply reflect the same underlying surveillance system at two different points in time, with the higher, more recent number being the more current and complete figure.

US Brain-Eating Amoeba Deaths and Survival Rate Statistics 2026

Source: CDC, PMC/Emerging Infectious Diseases journal, MDPI global systematic review (published March 2026)

Primary amebic meningoencephalitis remains one of the deadliest infections tracked in US public health surveillance, with a historical case fatality rate exceeding 97% — meaning that out of every roughly 40 people infected, fewer than one is expected to survive. Of the 167 confirmed US cases tracked between 1962 and 2025, only 4 people are known to have survived, a figure that has moved with painful slowness over recent decades even as overall medical care and diagnostic speed have improved across nearly every other area of infectious disease treatment.

A notable and encouraging data point comes from a global systematic review published in March 2026, which found meaningfully different survival outcomes by age group when examining cases from 2000 to 2024 worldwide: pediatric patients survived at a rate of 22%, compared to just 7.1% among adult patients. While these global figures are considerably higher than the roughly 2.4% survival rate implied by the smaller US-specific historical dataset, the gap likely reflects differences in case severity documentation, treatment access, and the tendency for milder or more successfully treated cases to be more thoroughly documented and published in recent international literature — underscoring that early diagnosis and treatment speed appear to meaningfully influence outcomes, particularly in younger patients.

US Brain-Eating Amoeba Cases by State Statistics 2026

Source: CDC state-of-exposure data (1937-2025), Becker’s Hospital Review, state health department reports

Consistent with the amoeba’s preference for warm freshwater, Texas and Florida have historically recorded the highest number of confirmed PAM cases in the country, followed by Virginia and California rounding out the four states with the most documented infections since national tracking began. This geographic concentration in warm-climate Southern and Gulf Coast states has remained the dominant pattern for decades, reflecting both the amoeba’s biological preference for water temperatures above 30°C (86°F) and the high volume of freshwater recreation — lakes, rivers, and reservoirs — common in these regions during long, hot summers.

However, public health officials have increasingly flagged a genuine northward expansion of confirmed cases in recent years, with states like Indiana, Ohio, Iowa, and Minnesota — regions not traditionally associated with brain-eating amoeba risk — reporting confirmed infections as rising average water temperatures create more hospitable conditions for the organism further from its historical Southern range. This trend continued directly into the current reporting period, with confirmed 2025-2026 cases identified in Missouri (linked to waterskiing at the Lake of the Ozarks), South Carolina, and most recently Louisiana, where the state health department confirmed a case tied to swimming in Lake Claiborne in Claiborne Parish on 19 August 2026 — illustrating that while Texas and Florida remain the historical epicenter, no region of the country with warm freshwater can be considered entirely risk-free.

US Brain-Eating Amoeba Cases by Age and Sex Statistics 2026

Source: CDC Naegleria fowleri Data page

The CDC’s age and sex breakdown of confirmed PAM cases reveals a striking and consistent pattern: males aged 10 to 14 years account for the single largest case category in the entire historical dataset, with 45 confirmed cases in that group alone — far more than any other age-sex combination tracked. More broadly, the CDC notes that male cases have exceeded female cases across nearly every age group examined, a pattern researchers generally attribute to boys and young men engaging in more frequent and more vigorous freshwater recreational activities — diving, jumping, and prolonged underwater play — that increase the likelihood of water forcefully entering the nasal passages compared to more passive water exposure.

Interestingly, the CDC’s own 2017 modeling-based estimate of the true annual case burden (roughly 16 cases per year, factoring in likely underdiagnosis) assumes a much more even split of 8 male and 8 female cases annually, suggesting that while confirmed, officially diagnosed cases skew heavily male, the true underlying infection rate by sex may be considerably closer to even — implying that female cases, along with adult cases more broadly, may be more likely to go undiagnosed or misattributed to other causes such as bacterial meningitis, given PAM’s difficult-to-distinguish early symptom presentation.

US Brain-Eating Amoeba Seasonal and Exposure Statistics 2026

Source: CDC Naegleria fowleri Data page, StatPearls (NCBI Bookshelf)

Seasonality is one of the most consistent and predictable patterns in the entire brain-eating amoeba dataset: of the 157 PAM cases where the month of illness onset was documented, a full 73% occurred during July and August, the peak of both summer water temperatures and freshwater recreational activity across the country. This tight seasonal clustering directly correlates with the amoeba’s biology — it proliferates most aggressively in water temperatures above 30°C (86°F) and can tolerate temperatures as high as 45°C (113°F), meaning the exact weeks when lake and river water is most inviting for swimmers are also the weeks when the organism is most abundant and active.

The overwhelming majority of documented US cases trace back to swimming in warm, fresh water such as lakes and ponds, though the CDC notes rarer exposure pathways have also been documented, including poorly maintained or under-chlorinated swimming pools, splash pads, and even tap water in isolated cases, typically involving nasal rinsing with unboiled tap water rather than filtered or distilled water. Critically, the amoeba cannot survive in salt water and does not pose a risk in properly maintained, adequately chlorinated pools, meaning ocean swimming and well-managed public or backyard pools remain effectively risk-free — an important distinction for parents and recreational swimmers trying to accurately assess where genuine risk does and does not exist.

US Brain-Eating Amoeba Treatment and Survivor Statistics 2026

Source: CDC clinical guidance, Cleveland Clinic, Infectious Disease Advisor, Emerging Infectious Diseases journal (CDC, 2026)

The current standard of care for PAM centers on the antifungal drug amphotericin B combined with miltefosine, an agent originally developed as a cancer treatment before being repurposed for parasitic infections and formally recommended by the CDC following two documented US survival cases in 2013. Beyond this core combination, CDC clinical guidance recommends supplementing treatment with azithromycin, fluconazole, rifampin, and dexamethasone, while some of the most successful historical recovery cases in North America — including cases involving children who recovered with minimal long-term impairment — also involved therapeutic hypothermia, deliberately cooling the patient’s body to reduce dangerous brain swelling alongside pharmacological treatment.

The most significant recent development in the treatment landscape is the emergence of nitroxoline, a decades-old antibiotic used in Europe for urinary tract infections, which laboratory studies beginning in 2023 showed could induce cell death in Naegleria fowleri at low concentrations without harming host cells. The CDC formally added nitroxoline to its recommended treatment regimen for the related brain-eating amoeba Balamuthia mandrillaris in 2025, and clinical case reports — including one documented in the CDC’s own Emerging Infectious Diseases journal in 2026 — describe patients showing continued clinical and radiographic improvement even while on nitroxoline monotherapy after other drugs were discontinued, suggesting the compound may represent a genuinely promising new tool for treating both Naegleria and Balamuthia infections in the years ahead, even though large-scale clinical trial data remains unavailable given how rare these infections are.

US Brain-Eating Amoeba Recent Case Reports 2025-2026

Source: CIDRAP, WJCL/Yahoo News, Louisiana Department of Health (19 August 2026 press release)

Recent case reports illustrate that brain-eating amoeba infections, while rare, continue to occur with grim regularity across multiple states each warm-weather season. In Missouri, health officials confirmed a lab-verified case in an adult resident whose infection was preliminarily linked to waterskiing at the Lake of the Ozarks, with the patient subsequently treated in an intensive care unit as officials continued investigating the precise source of exposure. In South Carolina, a child being treated at Prisma Health Children’s Hospital – Midlands in Columbia was confirmed to have contracted the infection during the week of July 7, and hospital officials later confirmed the child had died — a stark reminder that despite ongoing treatment advances, the disease’s underlying fatality rate remains extraordinarily high even with prompt hospital-based intervention.

The most recent confirmed case as of this report comes from Louisiana, where the state’s Department of Health announced on 19 August 2026 that a resident had contracted a confirmed Naegleria fowleri infection, with the likely source of exposure identified as swimming in Lake Claiborne located in Claiborne Parish shortly before the onset of illness. Because Naegleria fowleri infection is a reportable condition in the states where it is known to occur, health departments are generally required to publicly disclose confirmed cases, which is part of why this small number of infections — despite occurring only a handful of times nationally each year — consistently generates significant local and national media attention each summer, reinforcing public awareness of freshwater recreational risk even as the statistical probability of infection for any individual swimmer remains vanishingly small.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE